Bendamustine and Rituximab for the Treatment of Splenic Marginal Zone Lymphoma
Clinical trial NCT02853370 · COMPLETED
Trial details
- NCT number
- NCT02853370
- Sponsor
- International Extranodal Lymphoma Study Group (IELSG)
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2012-07-01
- Primary completion
- 2020-12-01
- Enrollment
- 78
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.